AstraZeneca Streamlines Further With Sale Of US Entocort Rights
This article was originally published in Scrip
Executive Summary
Continuing an effort to streamline assets, AstraZeneca PLC has divested US rights for its inflammatory bowel disease product Entocort (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn's disease, an area of medicine outside AstraZeneca's strategic focus. The sale, announced Nov. 23 for which Perrigo Company PLC paid $380m, follows the UK-based group's divestment in July of global rights to Entocort, excluding the US, to Tillotts Pharma AG for $215m in cash.